Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Net Income (2016 - 2025)

Historic Net Income for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$19.5 million.

  • Cartesian Therapeutics' Net Income fell 3010.27% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.7 million, marking a year-over-year increase of 5991.61%. This contributed to the annual value of -$77.4 million for FY2024, which is 6476.08% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Net Income stood at -$19.5 million for Q3 2025, which was down 3010.27% from -$20.1 million recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Net Income high stood at $15.0 million for Q2 2024, and its period low was -$196.7 million during Q4 2023.
  • Over the past 5 years, Cartesian Therapeutics' median Net Income value was -$12.2 million (recorded in 2024), while the average stood at -$17.4 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Net Income surged by 550566.8% in 2022 and then crashed by 343714.58% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' Net Income (Quarter) stood at $12.2 million in 2021, then plummeted by 51.85% to $5.9 million in 2022, then plummeted by 3437.15% to -$196.7 million in 2023, then surged by 87.66% to -$24.3 million in 2024, then rose by 19.6% to -$19.5 million in 2025.
  • Its last three reported values are -$19.5 million in Q3 2025, -$20.1 million for Q2 2025, and -$19.9 million during Q1 2025.